| Name | Mobocertinib |
|---|---|
| Synonyms |
Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-cboxylate
propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-cboxylate TAK-788 5-Pyrimidinecboxylic acid, 2-[[4-[[2-(dimethylamino)ethyl]methylamino]-2-methoxy-5-[(1-oxo-2-propen-1-yl)amino]phenyl]amino]-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester propan-2-yl 2-[(4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)phenyl)amino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-cboxylate Mobutinib 1-Methylethyl 2-[[4-[[2-(dimethylamino)ethyl]methylamino]-2-methoxy-5-[(1-oxo-2-propen-1-yl)amino]phenyl]amino]-4-(1-methyl-1H-indol-3-yl)-5-pyrimidinecboxylate TAK-788 (MOBOCERTINIB) ak-788 Mobotinib Mobocertinib (TAK788) TAK788 TAK-788 Mobocertinib, 10 mM in DMSO AP32788, MOBOCERTINIB AK-788 Mobocertinib (TAK788) ,S6813 Mobocertinib (TAK788, AP32788) Mobutinib TAK788 2H6]-Mobocertinib |
| Description | Mobocertinib is a potent epidermal growth factor receptor (EGFR) inhibitor and an antineoplastic agent, extracted from patent WO2019222093A1, compound A[1][2]. |
|---|---|
| Related Catalog | |
| References |
[1]. International Nonproprietary Names for Pharmaceutical Substances (INN). |
| Molecular Formula | C32H39N7O4 |
|---|---|
| Molecular Weight | 585.70 |